is paliperidone the antipsychotic most likely to raise prolactin, with others in the middle?
“pelliparidone, which is probably the worst offender, then you have in the middle a lens of pain, a le residone, a certain pain and a suppressorone”
a guest, a professor of psychiatry at Harvard Medical School said on Psychopharmacology and Psychiatry Updates, 2026-09-23, at 05:20. hear it in context →
the episode: Antipsychotics, Prolactin, and Sexual Side Effects (at 05:20). we link the show's own page; we do not re-host audio.
first, the part that holds
the headline point holds: in the largest network meta-analysis of oral antipsychotics, paliperidone raised prolactin more than any of the 32 drugs compared, and its us label says the same thing in plainer words. olanzapine, asenapine and sertindole also raised prolactin significantly in that analysis, at levels below the top group.
what we found when we went and looked
a 2019 network meta-analysis in the lancet (90 trials, 21,569 participants with usable prolactin data) found the largest mean prolactin rise with paliperidone, 48.51 ng/mL over placebo (95% ci 43.52 to 53.51), the highest of 32 drugs. olanzapine, asenapine, lurasidone, sertindole, haloperidol, amisulpride, risperidone and paliperidone all raised prolactin significantly, with means from 4.47 to 48.51 ng/mL. ziprasidone was not on that list. a cochrane review found it raised prolactin by about 4.8 ng/mL more than quetiapine and about 22 ng/mL less than risperidone. so the ranking is right at the top, and the "middle" grouping holds for olanzapine, asenapine and sertindole. calling ziprasidone intermediate goes further than the pooled data, and nothing we read checks the word "transient". the quote is a garbled transcript, so the drug names in the middle group are our best reading of it.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| paliperidone is probably the antipsychotic most likely to raise prolactin | confirmed | paliperidone had the largest mean prolactin rise of 32 oral antipsychotics, 48.51 ng/mL over placebo (43.52 to 53.51), based on 21,569 participants. the us label says paliperidone's effect is similar to risperidone's, 'a drug that is associated with higher levels of prolactin than other antipsychotic drugs.' limitation: these are short trials in adults with multi-episode schizophrenia, and risperidone sits close behind paliperidone. [1][2] |
| olanzapine, asenapine and sertindole cause an intermediate rise in prolactin | confirmed | all three were among the drugs with a significant prolactin rise, at levels below the paliperidone/risperidone/haloperidol/amisulpride top tier (the range for significant drugs started at 4.47 ng/mL). limitation: the text we read gives the range but not each drug's own number, so 'intermediate' rests on order, not on figures we could quote for each one. [1] |
| ziprasidone (the claim's reading of the garbled last drug name) causes an intermediate or transient rise in prolactin | overstated | ziprasidone was not among the drugs with a significant rise in the 32-drug network meta-analysis. in head-to-head trials it raised prolactin 4.77 ng/mL more than quetiapine (2 trials, n=754) and 21.97 ng/mL less than risperidone (2 trials, n=767). its label says it elevates prolactin but gives no size. its effect looks small, not middling, and none of the sources we read examined the word 'transient'. [1][3][4] |
| the middle group the speaker named is a lens of pain (olanzapine), a le residone, a certain pain (asenapine) and a suppressorone | unverifiable | the transcript is machine-garbled. 'a le residone' could be lurasidone or iloperidone, and 'suppressorone' could be ziprasidone or something else. lurasidone did raise prolactin significantly in the meta-analysis, so if that was the drug meant, the middle grouping fits it too. we could not hear the audio. [1] |
both directions
for the speaker: the 2019 network meta-analysis ranks paliperidone highest for prolactin rise of all 32 drugs, with a tight confidence interval. the us paliperidone label separately says it is in the highest prolactin tier. olanzapine, asenapine, sertindole and lurasidone all raised prolactin significantly, at lower levels, which matches a 'middle' group. the speaker hedged with 'probably', which fits paliperidone and risperidone being close.
against: ziprasidone did not reach significance for a prolactin rise in the pooled analysis, and head-to-head data put it far below risperidone, so 'intermediate' overstates it. the middle list also leaves out haloperidol and amisulpride, which belong near the top with risperidone, so a listener could come away thinking the top tier is paliperidone alone. none of the sources we read address 'transient' elevation.
what this cannot say
the meta-analysis covers short trials in adults with multi-episode schizophrenia. it reports mean changes, not rates of symptomatic hyperprolactinemia, and dose differences between trials affect where each drug ranks. we read the text and abstract, not each drug's number in the forest plot, so the middle-tier order rests on the significance list. the claim sentence is our reading of a garbled transcript, and the last drug in particular may not be ziprasidone. the label wording on paliperidone and risperidone is regulatory language, not a new head-to-head measurement.
sources, each one fetched and read
- network meta-analysis group, comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia, The Lancet 2019;394:939-951 What we read there: prolactin elevation (21 569 participants) from -77.05 ng/mL (clozapine) to 48.51 ng/mL (43.52 to 53.51; paliperidone); 'olanzapine, asenapine, lurasidone, sertindole, haloperidol, amisulpride, risperidone, and paliperidone were associated with significantly elevated prolactin levels (mean difference range 4.47-48.51 ng/mL)' Fetched 2026-10-20 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC6891890/
- us fda structured product label via openFDA, paliperidone extended-release tablets, section 5.7 hyperprolactinemia What we read there: 'paliperidone has a prolactin-elevating effect similar to that seen with risperidone, a drug that is associated with higher levels of prolactin than other antipsychotic drugs.' Fetched 2026-10-20 (HTTP 200). https://api.fda.gov/drug/label.json?search=openfda.generic_name:"paliperidone"+AND+openfda.route:"ORAL"&limit=1
- cochrane review CD006627, ziprasidone versus other atypical antipsychotics for schizophrenia What we read there: ziprasidone showed 'more prolactin increase than quetiapine (2 RCTs, n=754, MD 4.77 CI 1.37 to 8.16)' and 'less prolactin increase (2 RCTs, n=767, MD -21.97 CI -27.34 to -16.60) than risperidone' Fetched 2026-10-20 (HTTP 200). https://www.cochrane.org/evidence/CD006627_ziprasidone-versus-other-atypical-antipsychotics-schizophrenia
- us fda structured product label via openFDA, ziprasidone capsules, section 5.15 What we read there: 'as with other drugs that antagonize dopamine D2 receptors, ziprasidone elevates prolactin levels in humans.' Fetched 2026-10-20 (HTTP 200). https://api.fda.gov/drug/label.json?search=openfda.generic_name:"ziprasidone"&limit=1
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam